Commissioned research: AlzeCure Pharma
AlzeCure’s lead product asset, ACD855, started clinical development in late 2018 with the ambition to generate first clinical trials by early 2020.
However, early human exposure with the tablet product demonstrated that the concentration of the substance would require significantly longer dosing intervals than once daily, so the future development of the substance will now only be pursued with a formulation targeting ophthalmologic disorders.
Commissioned Research: Ascelia Pharma AB
Ascelia Pharma is a Swedish based oncology company in late-stage development with a primary focus on contrast enhanced liver MRI for those with severely impaired kidney function.
The company’s management has extensive experience from rare diseases at large corporations, including Genzyme (acquired by Sanofi) and Wilson Therapeutics (acquired by Alexion).
Commissioned Research: Bio-Works Technologies AB
Bio-Works is a Swedish-based supplier to biopharmaceutical producers, serving early-stage lab-scale to full-scale commercial producers. Its niche is the market for separation media used in protein purification.
The company started commercial sales in 2014. Market demand is driven by increased production volumes of biopharmaceutical products including biosimilars, and productivity investments.
Commissioned research: Immunovia AB
Immunovia is a Swedish-based diagnostic company in late-stage development for products for early detection of diseases within the oncology and autoimmune areas, with a primary target on early detection of pancreas cancer.
The company’s management team has extensive diagnostics company background, including GE Healthcare and DAKO (aquired by Agilent)
Commissioned research: AlzeCure Pharma
AlzeCure Pharma is a Swedish-based pharmaceutical company with potentially first-in-class proprietary and novel targeted small molecule (tablets) candidates for neurodegenerative diseases with a primary target on Alzheimer’s Disease (AD).
AlzeCure’s management team has extensive big pharma experience, and formed an integral part of AstraZeneca’s CNS department.